Advertisement
Home »

Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint Inhibitor.

Apr 24, 2023

ABOUT THE CONTRIBUTORS

  • Yousef Zakharia

    University of Iowa, Holden Comprehensive Cancer Center, Iowa City, IA. Electronic address: yousef-zakharia@uiowa.edu.

    Lynn Huynh

    Analysis Group, Inc, Boston, MA. Electronic address: Lynn.Huynh@analysisgroup.com.

    Shawn Du

    Analysis Group, Inc, New York, NY.

    Rose Chang

    Analysis Group, Inc, Boston, MA.

    Selina Pi

    Analysis Group, Inc, New York, NY.

    Sanjana Sundaresan

    Analysis Group, Inc, Boston, MA.

    Mei S Duh

    Analysis Group, Inc, Boston, MA.

    Giovanni Zanotti

    Pfizer, Inc, New York, NY.

    Despina Thomaidou

    Pfizer Hellas, Athens, Greece.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement